1. 原发性肺癌诊疗规范(2018年版) 2. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for PatientsWith Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: ResultsFrom the Phase I KEYNOTE-001 Study. J Clin Oncol, Published online on 2 June,2019. DOI: 10.1...
参考文献: FDA approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) 我们特别建了“患者交流群”,欢迎肿瘤患者/家属扫描下方二维码,加入交流...
KEYTRUDA may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “nonsquamous” and your tumor does not have an abnormal “EGFR” or “ALK” gene. KEYTRUDA may be used with the ch...
See how the support of the people who love her helps Teresa stay positive and determined as they face advanced non–small cell lung cancer together. Read Teresa’s story Patient supportthroughout your treatment Patients who have been prescribed KEYTRUDA for an approved indication can access addition...
7. L. Paz‑Ares, et al., Pembrolizumab plus Chemotherapy for SquamousNon–Small-Cell Lung Cancer. N Engl J Med, 2018. 10.1056/NEJMoa1810865
原文出处:FDA approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) 原标题:鳞状肺癌一线免疫治疗重大进展!默沙东Keytruda(可瑞达)获美国FDA批...
成功研究多为单药或者联合化疗用于非驱动突变NSCLC,覆盖后线单药,一线单药,一线联合到辅助单药、围术期新辅助联合化疗/辅助单药,涉及Keynote-010、Keynote-024、Keynote-042、Keynote-189/407、Keynote-091/671系列经典研究;失败的为探索联合仑伐替尼、奥拉帕利新组合...
(见:单药打江山!Keytruda一线治疗NSCLC显著改善总生存期) 信息来源:Merck’s KEYTRUDA? (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial...
原文出处:Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权...
expansion of its blockbuster PD-1 inhibitor Keytruda (pembrolizumab). The drug isnowapproved in combination with chemotherapy (carboplatin and paclitaxel) for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC), a difficult to treat lung cancer population....